secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2026-10-14T13:00:14+00:00
Accession:  0001193125-26-421079
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Ultragenyx to sell FDA rare pediatric disease PRV for $203M in cash
-------------------------------------------------------------------

- Asset purchase agreement signed October 8, 2026; unnamed buyer pays $203 million in cash at closing.
- PRV was awarded by the FDA on September 17, 2026 with approval of FAYUVI (rebisufligene etisparvovec-hopf), also known as UX111.
- FAYUVI/UX111 treats pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome Type A).
- Closing subject to expiration or termination of the HSR antitrust waiting period; agreement to be filed with the FY2026 Form 10-K.
- Pact includes customary representations, warranties, covenants and indemnification provisions subject to limitations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000119312526421079/0001193125-26-421079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000119312526421079/rare-20261008.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-421079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer